<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2025.1666973</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pathological diversity of pulmonary sarcoidosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Takemura</surname> <given-names>Tamiko</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3135488"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Department of Pathology, Kanagawa Cardiovascular and Respiratory Center</institution>, <city>Yokohama</city>, <state>Kanagawa</state>, <country country="jp">Japan</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Tamiko Takemura, <email xlink:href="mailto:tamikobyori@gmail.com">tamikobyori@gmail.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-27">
<day>27</day>
<month>11</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1666973</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>11</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Takemura.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Takemura</copyright-holder>
<license>
<ali:license_ref start_date="2025-11-27">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Sarcoidosis is a multisystem disease characterized histologically by the presence of non-caseating epithelioid cell granulomas. Although the etiology of sarcoidosis remains uncertain, <italic>Cutibacterium acnes</italic> (formerly known as <italic>Propionibacterium acnes</italic>) and mycobacteria are considered putative pathogenic antigens in sarcoidosis. Sarcoidosis must be differentiated from a variety of granulomatous diseases of the lung. The granulomas in pulmonary sarcoidosis are frequently located in the broncho-vascular bundles, interlobular septa, and alveoli, and there is frequent vascular involvement in the form of granulomatous angiitis. While most granulomas may spontaneously or with treatment disappear, some along the broncho-vascular bundles and interlobular septa often become fibrotic. In the chronic fibrotic stage, the upper lobes of the lungs become scarred and contracted, with fibrous bands seen between the hilar regions and pleura. Cystic changes and, occasionally, honeycombing are seen in the lung. Granulomatous vascular involvement is frequently seen in the lung. The microangiopathy of sarcoidosis is characterized by endothelial injury and multilamellation of the basement membrane of microvessels and has been observed electron microscopically in the heart, lung, eye, and skin specimens. The pathogenetic correlation between granulomas and microangiopathy remains to be resolved.</p>
</abstract>
<kwd-group>
<kwd>sarcoidosis</kwd>
<kwd>lung</kwd>
<kwd>epithelioid cell granuloma</kwd>
<kwd>fibrosis</kwd>
<kwd>granulomatous angiitis</kwd>
<kwd>pathology</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement>
</funding-group>
<counts>
<fig-count count="10"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="46"/>
<page-count count="10"/>
<word-count count="5224"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pathology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Sarcoidosis is a multisystem disease that affects multiple organs and is characterized by non-caseating epithelioid cell granulomas in the affected organs (<xref ref-type="bibr" rid="ref1">1</xref>). The precise etiology of sarcoidosis remains unknown, and many pathogens, including mycobacteria, have been implicated over the years.</p>
<p>In Japan, <italic>Cutibacterium acnes</italic> (formerly known as <italic>Propionibacterium acnes</italic>) is the only bacterium that has consistently been isolated from sarcoid lesions (<xref ref-type="bibr" rid="ref2">2</xref>), and its presence has been confirmed by molecular studies, including PCR and <italic>in situ</italic> hybridization (<xref ref-type="bibr" rid="ref3 ref4 ref5">3&#x2013;5</xref>). Negi et al. (<xref ref-type="bibr" rid="ref6">6</xref>) demonstrated the localization of <italic>C. acnes</italic> in granulomas, and Eishi (<xref ref-type="bibr" rid="ref7">7</xref>) subsequently reviewed the etiologic link. However, outside of Japan, other microorganisms, including mycobacterial antigens, have also been implicated, and the etiology of sarcoidosis remained unresolved until date (<xref ref-type="bibr" rid="ref8 ref9 ref10 ref11">8&#x2013;11</xref>). Although the etiology of sarcoidosis remains unresolved until now, Sawahata et al. (<xref ref-type="bibr" rid="ref12">12</xref>) recently reviewed latent microbial reactivation and immune dysregulation in sarcoidosis, focusing on <italic>C. acnes</italic>.</p>
<p>Sarcoidosis can affect multiple organs, including the lungs, lymph nodes, heart, eyes, and skin. Pulmonary involvement is of major clinical significance, as the lesions could progress to intractable fibrosis and cyst formation in the lungs. This review describes the pathological diversity of sarcoid lesions in the lungs, with particular emphasis on pulmonary fibrosis and vascular involvement, mainly based on autopsy of cases of Japanese patients with sarcoidosis.</p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Incidence and characterization of sarcoidosis in Japan</title>
<p>Ethnic differences are known to exist in the clinical features of sarcoidosis. Recent epidemiological surveys in Japan (<xref ref-type="bibr" rid="ref13">13</xref>) have revealed that sarcoidosis occurs at an incidence of 1.01 per 100,000 population in Japan with a male-to-female ratio of 0.73:1.28. Morimoto reported a peak prevalence of sarcoidosis between 20 and 34&#x202F;years of age in men and between 50 and 69&#x202F;years of age in women (<xref ref-type="bibr" rid="ref13">13</xref>). The organs most frequently affected, in addition to the lungs, are the eyes, skin, and heart. Sawahata et al. (<xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref15">15</xref>) analyzed the relationship between the stage of illness based on diagnostic imaging findings and age and found that stage 1 or 2 predominantly occur in persons 45&#x202F;years old or under and that stage 3 and 4 diseases predominantly occur in the elderly age group.</p>
<p>Iwai et al. (<xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref17">17</xref>) investigated the autopsy findings of sarcoidosis in Japan between 1958 and 1989 and reported that both the distribution of granulomas in the body and the fatality rate tended to be higher among cases with cardiac sarcoidosis. Tachibana conducted autopsy investigations of sarcoidosis in patients who had died at 80&#x202F;years later and reported that a high percentage of the patients had died from cardiac lesions (77%), and that malignant neoplasm was the most frequent cause of death after sarcoidosis in these patients (<xref ref-type="bibr" rid="ref18">18</xref>).</p>
</sec>
<sec id="sec3">
<label>3</label>
<title>Biopsy techniques for the diagnosis of pulmonary sarcoidosis</title>
<p>A Case-Controlled Etiologic Study of Sarcoidosis conducted in 2005 showed that biopsies of different sites of the body had been performed to make a definitive diagnosis of sarcoidosis (<xref ref-type="bibr" rid="ref19">19</xref>). Biopsies within the thoracic cavity are the most frequently performed to identify non-caseating epithelioid cell granulomas. Since granulomas associated with various diseases can be detected in various organs, a differential diagnosis of sarcoidosis from other granulomatous diseases is necessary (<xref ref-type="bibr" rid="ref20">20</xref>). The scalene lymph node biopsy was often used as a diagnostic procedure in the past, and then, the biopsy of the mediastinal lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been often applied (<xref ref-type="bibr" rid="ref21">21</xref>). Although granulomas can be identified and clearly diagnosed by EBUS-TBNA, evaluation of the entire lymph node structure is often difficult. At present, transbronchial lung biopsy and transbronchial lung cryobiopsy are the most frequently used procedures to diagnose pulmonary sarcoidosis (<xref ref-type="bibr" rid="ref22">22</xref>).</p>
</sec>
<sec id="sec4">
<label>4</label>
<title>Morphological characteristics of the granulomas</title>
<p>Granulomas in sarcoidosis are formed by the aggregation of macrophage-derived epithelioid cells as a result of a Th1 immune reaction induced by antigen presentation to T lymphocytes. This can be viewed as the morphological form of a host defense mechanism that isolates the body from the pathogens (<xref ref-type="bibr" rid="ref11">11</xref>). Regulatory T cells and macrophages play a major role in granuloma formation (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). Most of the granulomas in sarcoidosis consist of solitary granuloma measuring 200&#x2013;300 &#x03BC;m in size or conglomerated ones composed of non-caseating epithelioid cells (<xref ref-type="bibr" rid="ref25">25</xref>). Epithelioid cell granulomas are well demarcated from the surrounding tissues, and silver impregnation staining reveals argyrophilic fibers in a basket-like form. Well-developed subplasmalemmal linear densities are seen between adjacent epithelioid cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The granulomas contain lymphocytes and Langhans giant cells in addition to epithelioid cells. CD4+ T lymphocytes are distributed within the granulomas, whereas CD8+ T lymphocytes are distributed at the margin of the granulomas. Granular substances have been detected in the sarcoid granulomas within the lung with the use of a monoclonal antibody to lipoteicoic acid of <italic>C. acnes</italic> (<xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref7">7</xref>) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Epithelioid cell granuloma in the mediastinal lymph node in a case of sarcoidosis. <bold>(a)</bold> Epithelioid cell granuloma measuring 200&#x202F;&#x03BC;m in diameter (hematoxylin&#x2013;eosin stain, &#x00D7; 20). <bold>(b)</bold> Argyrophilic fibers encircling a granuloma in a basket-like form (silver impregnation stain, &#x00D7; 20). <bold>(c)</bold> Subplasmalemmal linear densities (arrows) are visible between adjacent epithelioid cells (transmission electron microscopy, &#x00D7; 10,000).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three-panel image showing histological and electron microscopy findings. Panel (a) displays a few granulomas, with dense clusters of cells stained pink and purple. Panel (b) shows a silver-stained micrograph highlighting network-like structures. Panel (c) illustrates an electron micrograph with two black arrows pointing to a specific elongated structure amidst a granular background.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Non-caseating epithelioid cell granulomas in the lung that contain fine granular materials show positive immunohistochemical staining with a monoclonal antibody directed against lipoteicoic acid of <italic>C. acnes</italic> (immunohistochemistry &#x00D7; 20; Inset. &#x00D7; 40).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Immunohistochemial tissue section showing  a dense arrangement of cells stained in light brown with scattered darker brown spots, indicative of a specific protein expression. An inset on the right magnifies a section, highlighting more concentrated dark brown staining against a lighter cellular background.</alt-text>
</graphic>
</fig>
<sec id="sec5">
<label>4.1</label>
<title>Inclusion bodies in granulomas</title>
<p>The giant cells in sarcoid granulomas often contain inclusion bodies such as Schaumann bodies (conchoidal bodies) that measure 25&#x2013;200 &#x03BC;m in size and possess a lamellar structure containing iron and calcium (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Schaumann bodies are very common in sarcoidosis, but they are also seen in the granulomas associated with tuberculosis, berylliosis, and occasionally, hypersensitivity pneumonitis. Asteroid bodies are star-shaped inclusion bodies noted within multinucleated giant cells that measure 5&#x2013;30 &#x03BC;m in size and are arranged in a radiating manner; they are seen in 2&#x2013;9% of all sarcoid granulomas (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). Asteroid bodies are composed of ubiquitin and myelin sheath-like membranous material and can also be found in tuberculosis, histoplasmosis, lepromas, and foreign body granulomas (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Variable morphologies of granulomas in the mediastinal lymph node and lung. <bold>(a)</bold> A giant cell with a Schaumann body in the mediastinal lymph node. (hematoxylin&#x2013;eosin stain, &#x00D7; 40). <bold>(b)</bold> An asteroid body in a giant cell in an epithelioid cell granuloma. (Hematoxylin&#x2013;eosin stain, &#x00D7; 40). <bold>(c)</bold> Hyalinization of granulomas with a multinucleated giant cell in the mediastinal lymph node. (Hematoxylin&#x2013;eosin stain, &#x00D7; 10). <bold>(d)</bold> A fibrotic granuloma with a few giant cells in an alveolus. (Hematoxylin&#x2013;eosin stain, &#x00D7; 20).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four microscopic images labeled a, b, c, and d, show tissue samples with varying cell densities and structures. Image a depicts dense, red-stained cells surrounding a central structure. Image b features a mix of light pink and purple-stained cells with circular patterns. Image c displays tightly packed dark and pink cells with distinct round formations. Image d shows regressive phase of granuloma with fibrosis.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec6">
<label>4.2</label>
<title>Hyalinization and necrosis of granulomas</title>
<p>Most sarcoid granulomas regress spontaneously but persist in the form of hyalinized nodules (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). The granulomas in sarcoidosis have generally been described as non-necrotic epithelioid cell granulomas, but necrosis within the granulomas of sarcoidosis has also been reported in approximately 3&#x2013;30% of cases (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
</sec>
<sec id="sec7">
<label>4.3</label>
<title>Fibrosis of granulomas</title>
<p>Most granulomas in sarcoidosis resolve when the antigen is eliminated. Some granulomas develop fibrosis, often with remaining giant cells and lymphocytes (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). The process of fibrosis of granuloma in pulmonary sarcoidosis may be induced by a dysregulated immune response. Th1-mediated immune reaction results in activation of fibroblasts. Various fibrogenic cytokines, such as TGF-&#x03B2;, TNF-&#x03B1;, IL-1&#x03B2;, and IL-6, are derived from the constituent cells of granuloma, and they are considered to be fibrogenic factors (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref26 ref27 ref28 ref29">26&#x2013;29</xref>).</p>
</sec>
</sec>
<sec id="sec8">
<label>5</label>
<title>Distribution of sarcoid granulomas in the lung</title>
<p>The granulomas in pulmonary sarcoidosis are primarily distributed along the lymphatic vessels, namely in the bronchovascular bundles, bronchiolar walls, interlobular septa, and the pleura (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Granulomas are also detected within the lymphatic vessels and in the alveoli. Analyses of transbronchial lung biopsy specimens have revealed that the granulomas in the lungs are predominantly distributed in the upper lobes (<xref ref-type="bibr" rid="ref30">30</xref>). In nodular sarcoidosis, granulomas involve the alveolar lumina and destroy the alveolar architecture, often leading to intense fibrosis. Moreover, the granulomas around the bronchovascular bundles sometimes compress the bronchial and bronchiolar tree and cause upper lobe collapse.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Characteristic distribution of granulomas in the lung, mainly in the interlobular septa, with vascular involvement (Elastica van Gieson stain, &#x00D7; 2.5). V, interlobular vein.</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Microscpic image of distribution of granulomas in the lung. Two elonngated structires maked with "V" indicate interlobular pulmonary veins.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec9">
<label>6</label>
<title>Fibrotic sequelae in pulmonary sarcoidosis</title>
<p>Akira et al. (<xref ref-type="bibr" rid="ref31">31</xref>) conducted long-term follow-up computed tomography evaluation of pulmonary sarcoidosis and showed peribronchial conglomeration with shrinkage of the lung. We conducted a pathological investigation of the fibrosis pattern and remodeling of the lungs in 66 autopsy cases of sarcoidosis in Japan (<xref ref-type="bibr" rid="ref32">32</xref>).</p>
<sec id="sec10">
<label>6.1</label>
<title>Histological patterns of fibrosis associated with granulomas in the lung</title>
<p>The histological patterns of fibrosis associated with granuloma formations and remodeling of the lungs in sarcoidosis are shown in <xref ref-type="table" rid="tab1">Table 1</xref> (<xref ref-type="bibr" rid="ref32">32</xref>). Stellate fibrosis is the most frequent type of fibrosis that occurs after the subsidence of a granuloma. Stellate fibrosis primarily occurs at the sites of granulomas along the bronchioles and pulmonary arteries and is also seen in the alveolar ducts (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Stellate fibrosis is the type of fibrosis seen in 95% of cases of pulmonary sarcoidosis and in 77% of cases in which the sarcoidosis does not predominantly affect the lungs, i.e., cardiac cases or nervous system. Bronchovascular fibrosis is observed primarily along the bronchioles and pulmonary arteries (<xref ref-type="fig" rid="fig5">Figure 5b</xref>) and was seen in 85% of cases of pulmonary sarcoidosis. Thick band-like collapse fibrosis (<xref ref-type="fig" rid="fig5">Figure 5c</xref>) was observed in 70% of cases of pulmonary sarcoidosis.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Pathological features of the lung in 66 autopsy cases of sarcoidosis (<xref ref-type="bibr" rid="ref32">32</xref>).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">Stellate fibrosis (%)</th>
<th align="center" valign="top">Band-like fibrosis (%)</th>
<th align="center" valign="top">Bronchovascular bundle fibrosis (%)</th>
<th align="center" valign="top">Collapse of bronchovascular bundle (%)</th>
<th align="center" valign="top">Upper lobe contraction (%)</th>
<th align="center" valign="top">Cavity (%)</th>
<th align="center" valign="top">Bulla (%)</th>
<th align="center" valign="top">Bronchiectasis (%)</th>
<th align="center" valign="top">Honeycombing (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Pulmonary sarcoidosis (<italic>n</italic>&#x202F;=&#x202F;20)</td>
<td align="char" valign="top" char="(">19 (95)</td>
<td align="center" valign="top">17 (85)</td>
<td align="char" valign="top" char="(">16 (80)</td>
<td align="char" valign="top" char="(">14 (70)</td>
<td align="char" valign="top" char="(">13 (65)</td>
<td align="center" valign="top">9 (45) Aspergillus 8 (40)</td>
<td align="center" valign="top">11 (55)</td>
<td align="center" valign="top">13 (65)</td>
<td align="char" valign="top" char="(">10 (50)</td>
</tr>
<tr>
<td align="left" valign="top">Cardiac sarcoidosis (<italic>n</italic>&#x202F;=&#x202F;31)</td>
<td align="char" valign="top" char="(">21 (68)</td>
<td align="center" valign="top">8 (26)</td>
<td align="char" valign="top" char="(">13 (42)</td>
<td align="char" valign="top" char="(">5 (16)</td>
<td align="char" valign="top" char="(">10 (32)</td>
<td align="center" valign="top">1 (3)</td>
<td align="center" valign="top">5 (16)</td>
<td align="center" valign="top">1 (3)</td>
<td align="char" valign="top" char="(">1 (3)</td>
</tr>
<tr>
<td align="left" valign="top">Neurosarcoidosis (<italic>n</italic>&#x202F;=&#x202F;3)</td>
<td align="char" valign="top" char="(">3 (100)</td>
<td align="center" valign="top">0</td>
<td align="char" valign="top" char="(">3 (100)</td>
<td align="char" valign="top" char="(">2 (67)</td>
<td align="char" valign="top" char="(">2 (67)</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="char" valign="top" char="(">1 (33)</td>
</tr>
<tr>
<td align="left" valign="top">Sarcoidosis without special organ involvement (<italic>n</italic>&#x202F;=&#x202F;12)</td>
<td align="char" valign="top" char="(">8 (67)</td>
<td align="center" valign="top">3 (25)</td>
<td align="char" valign="top" char="(">6 (50)</td>
<td align="char" valign="top" char="(">4 (33)</td>
<td align="char" valign="top" char="(">1 (8)</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1 (8)</td>
<td align="char" valign="top" char="(">1 (8)</td>
</tr>
<tr>
<td align="left" valign="top">Total 66 (female 45, male 21)</td>
<td align="char" valign="top" char="(">51 (77)</td>
<td align="center" valign="top">28 (42)</td>
<td align="char" valign="top" char="(">38 (58)</td>
<td align="char" valign="top" char="(">25 (38)</td>
<td align="char" valign="top" char="(">26 (39)</td>
<td align="center" valign="top">10 (15) Aspergillus 8 (12)</td>
<td align="center" valign="top">16 (24)</td>
<td align="center" valign="top">15 (23)</td>
<td align="char" valign="top" char="(">13 (20)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Fibrous sequelae of granulomas in the autopsied lung. <bold>(a)</bold> Stellate fibrosis at the respiratory bronchiole (Elastica van Gieson stain, &#x00D7; 5). <bold>(b)</bold> Bronchovascular fibrosis (Elastica van Gieson stain, &#x00D7; 1). <bold>(c)</bold> Collapse fibrosis along the bronchovascular bundle in the upper lobe (Elastica van Gieson stain, &#x00D7; 5).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Microscopic images show various fibrotic patterns. Image a displays stelalte fibrosis, image b highlights peribronchial fibrosis, and image c shows bronchovascualr collapse.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec11">
<label>6.2</label>
<title>Bronchovascular bundle fibrosis and its sequelae</title>
<p>Bronchovascular bundle fibrosis develops predominantly in the upper lobes, resulting in contraction of the upper lobes of the lungs. Sawahata et al. (<xref ref-type="bibr" rid="ref33">33</xref>) recently reported characteristic central-peripheral fibrotic bands with upper lobe shrinkage in patients with long-standing sarcoidosis. Kawanobe et al. (<xref ref-type="bibr" rid="ref34">34</xref>) also described central bronchial deformity on chest radiographs in pulmonary sarcoidosis as a crucial phenotype of upper lobe fibrotic changes. Upper lobe contraction has been estimated to occur in 65% of cases of pulmonary sarcoidosis and 32% of cases with cf. cardiac sarcoidosis. These cases present segmental bronchial stenosis secondary to hilar lymph node enlargement and bronchovascular bundle fibrosis (<xref ref-type="fig" rid="fig6">Figures 6a</xref>,<xref ref-type="fig" rid="fig6">b</xref>). Among the 13 cases of pulmonary sarcoidosis that presented with upper lobe contraction, 9 cases exhibited cavity formation as well. These nine cases were accompanied by <italic>Aspergillus</italic>. Cyst formation was noted in 11 cases (55%) of pulmonary sarcoidosis (<xref ref-type="table" rid="tab1">Table 1</xref>). The cystic lesions are likely a result of check-valve mechanisms that develop as a result of advanced fibrosis of the wall of the proximal bronchi.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Upper lobe contraction in a 60-year-old man with a 40-year history of pulmonary sarcoidosis. <bold>(a)</bold> Marked bilateral shrinkage of the upper lobes with fibrous involvement of the hilar lymph nodes and bronchiolar dilatation. <bold>(b)</bold> Peribronchial dense fibrosis and dilatation of the bronchial lumina, extending from the hilar region to the pleura, indicated by the square in the left upper lobe (Elastica van Gieson, &#x00D7; 1).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g006.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Cut section of the bilateral lung with dense fibrosis of the hilar region. The right figure (b)isindicated by yellow square of ashows dilatation of bronchus.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec12">
<label>6.3</label>
<title>Honeycomb lesions in pulmonary sarcoidosis</title>
<p>The honeycomb lesions in sarcoidosis are not confined to the lower lobe of the lung and often predominate in the upper lobe (<xref ref-type="fig" rid="fig7">Figures 7a</xref>,<xref ref-type="fig" rid="fig7">b</xref>) (<xref ref-type="bibr" rid="ref35">35</xref>). Histologically, the normal alveolar architecture is lost, replaced by enlarged airspaces, connecting to bronchioles without the obviously collapsed perilobular alveoli, seen in usual interstitial pneumonia (UIP) (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). However, Shigemitsu et al. reported (<xref ref-type="bibr" rid="ref36">36</xref>, <xref ref-type="bibr" rid="ref37">37</xref>) some cases of pulmonary sarcoidosis showing honeycombing with fibroblastic foci in the lower lobe, resembling those of idiopathic pulmonary fibrosis.</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>Bilateral upper lobe contraction with honeycomb-like lesion in a 40-year-old woman with a 27-year history of pulmonary sarcoidosis. <bold>(a)</bold> Honeycomb-like lesion involving almost the entire upper lobes bilaterally. <bold>(b)</bold> Close-up view of the right upper lobe showing a honeycomb-like appearance. <bold>(c)</bold> Pulmonary lobules containing irregularly sized cystic lesions, probably connected to the bronchioles but without perilobular alveolar collapse, different from the pattern of honeycombing observed in idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) (Elastica van Gieson stain, &#x00D7; 1.5).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g007.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three-panel image illustrating lung damage. Panel a: Cross-section of the lung showing contraction of upper lobes with honeycomb-like appearance. Panel b: Close-up of fibrotic and cavitary lung tissue texture. Panel c: Histological section with bronchioles (labeled "br") amidst spaces, demonstrating structural breakdown.</alt-text>
</graphic>
</fig>
<p>Coexistence of sarcoidosis and interstitial pneumonia has been reported (<xref ref-type="bibr" rid="ref38">38</xref>, <xref ref-type="bibr" rid="ref39">39</xref>). Tachibana also reported acute exacerbation occurring in cases with lower lung-dominant sarcoidosis (<xref ref-type="bibr" rid="ref40">40</xref>).</p>
</sec>
</sec>
<sec id="sec13">
<label>7</label>
<title>Vascular involvement in pulmonary sarcoidosis</title>
<sec id="sec14">
<label>7.1</label>
<title>Granulomatous angiitis and its sequelae</title>
<p>Granulomatous vascular involvement is one of the characteristic lesions of pulmonary sarcoidosis (<xref ref-type="bibr" rid="ref41">41</xref>, <xref ref-type="bibr" rid="ref42">42</xref>). Granulomatous angiitis associated with sarcoidosis is characterized by granuloma formation in the vascular wall with destruction of the elastic fibers and/or smooth muscles of the vascular wall; no neutrophil infiltration or necrosis is observed. Vascular involvement with granuloma formation has been observed in transbronchial lung biopsy specimens (<xref ref-type="bibr" rid="ref30">30</xref>), as well as autopsy specimens (<xref ref-type="bibr" rid="ref42">42</xref>). Granulomatous involvement and its sequelae extend from the larger blood vessels, namely the pulmonary arteries and veins in the hilar region to the smaller blood vessels throughout the lung, with particularly marked involvement of the interlobular veins and intralobular arteries (<xref ref-type="bibr" rid="ref42">42</xref>) (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Scarring of the vascular wall resulting from healing of granulomatous angiitis was often noted in autopsied lungs, without the regeneration of the elastic fibers and smooth muscles of the vascular wall destroyed by granuloma formation and prominent deposition of collagen fibers.</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption>
<p>Granulomatous angiitis in pulmonary sarcoidosis. <bold>(a)</bold> Granulomatous involvement of a medium-sized pulmonary artery with destruction of the media and outer elastic lamina (Elastica van Gieson stain, &#x00D7; 10). <bold>(b)</bold> Scarred lesion resulting from granulomatous involvement of a pulmonary artery with dense deposition of collagen in the media and adventitia (Elastica van Gieson stain, &#x00D7; 10). <bold>(c)</bold> Granulomatous involvement of an interlobular vein with the destruction of the elastic lamina (Elastica van Gieson stain, &#x00D7; 10). <bold>(d)</bold> Scarring of an interlobular vein showing dense fibrosis in the venous wall and surrounding interstitium (Elastica van Gieson stain, &#x00D7; 10).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g008.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four-panel images showing histological section sof arteries (a,b) and veins(c.d).  Panel a and c shows granulomas in the vascualr walls. Panel b and d shows scar phase of grnaulomatous involvement of artery and vein.</alt-text>
</graphic>
</fig>
<p>Pulmonary hypertension in sarcoidosis has been known as sarcoidosis-associated pulmonary hypertension (SAPH) and is an important complication of advanced sarcoidosis (<xref ref-type="bibr" rid="ref43">43</xref>). SAPH may be induced by multifaceted causes, such as granulomatous angiitis, veno-occlusive disease, pulmonary embolism, interstitial lung disease, and extrapulmonary disease, including left ventricular systolic and diastolic dysfunction. Thus, the cases with granulomatous vascular involvement must be carefully followed up to develop into pulmonary hypertension.</p>
</sec>
<sec id="sec15">
<label>7.2</label>
<title>Microangiopathy in sarcoidosis</title>
<p>Microangiopathy in sarcoidosis has been observed clinically in the form of vascular lesions in the ocular fundus, a hexagonal pattern of dilatation of the bronchial mucosal vessels, and Raynaud&#x2019;s phenomenon in the skin. Electron microscopic observations have revealed endothelial cell degeneration and multilayering of the basement membranes of small blood vessels (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref44">44</xref>, <xref ref-type="bibr" rid="ref45">45</xref>) (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Microangiopathic changes have been observed in the myocardium, skin, skeletal muscles, and bronchial mucosa in patients with sarcoidosis. In regard to the etiology of microangiopathy associated with sarcoidosis, it has been considered that vascular endothelial cell growth factors released from the constituent cells of granuloma and their receptors in the microcirculation system could be involved (<xref ref-type="bibr" rid="ref46">46</xref>). However, further studies of microangiopathy are needed.</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption>
<p>Microangiopathy of a capillary in the bronchial mucosa. Swelling of endothelial cells with multilayering of the basement membrane of a capillary in the bronchial mucosa (&#x00D7;10,000).</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g009.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Electron micrograph showing the complex structure of connective tissue. It features elongated, intertwined fibers and several round and oval cellular components, resembling cells and extracellular matrix. Dense areas contrast with lighter spaces, illustrating varied textures.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="conclusions" id="sec16">
<label>8</label>
<title>Conclusion</title>
<p>I acknowledge that this pathological review of pulmonary sarcoidosis is limited to the Japanese patients, especially regarding the Japanese autopsy cases of sarcoidosis. In this paper, we have described the pathological features in the lung in patients with sarcoidosis, focusing on various fibrotic sequelae of epithelioid cell granulomas and remodeling of the lung. Granuloma-derived fibrosis predominantly involves the upper lobe bronchi from the hilar region to the pleura, resulting in upper lobe contraction and occasionally, formation of honeycomb-like lesions. <xref ref-type="fig" rid="fig10">Figure 10</xref> shows a scheme of multifaceted pulmonary lesions derived from granulomas in sarcoidosis. Further research is necessary to resolve the process from granuloma to fibrosis and to prevent progressive fibrosis in pulmonary sarcoidosis.</p>
<fig position="float" id="fig10">
<label>Figure 10</label>
<caption>
<p>Sequelae of granuloma formation in pulmonary sarcoidosis. Some granulomas regress, while confluent granulomas involving the broncho-vascular bundles often progress to stellate or band-like fibrosis and collapse, resulting in bronchiectasis, upper lobe contraction, honeycombing, cyst formation, and cavitation.</p>
</caption>
<graphic xlink:href="fmed-12-1666973-g010.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Flowchart illustrating the progression from a causative agent, C. acnes, to various pulmonary conditions. It begins with lymphocyte, monocytes, and macrophage activation leading to epithelioid cell granuloma. This branches into confluent granuloma with broncho-vascular involvement, solitary granuloma, and fibrosing alveolitis, resulting in conditions like stellate fibrosis, upper lobe contraction, broncho-bronchiolectasis, and honeycomb lesions.</alt-text>
</graphic>
</fig>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="sec17">
<title>Author contributions</title>
<p>TT: Writing &#x2013; review &#x0026; editing, Investigation, Writing &#x2013; original draft.</p>
</sec>
<sec sec-type="COI-statement" id="sec18">
<title>Conflict of interest</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec19">
<title>Generative AI statement</title>
<p>The author declare that no Gen AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec20">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunninghake</surname> <given-names>GW</given-names></name> <name><surname>Costabel</surname> <given-names>U</given-names></name> <name><surname>Ando</surname> <given-names>M</given-names></name> <name><surname>Baughman</surname> <given-names>R</given-names></name> <name><surname>Cordier</surname> <given-names>JF</given-names></name> <name><surname>du Bois</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS) and the European respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>1999</year>) <volume>160</volume>:<fpage>736</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1164/ajrccm.160.2.ats4-99</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname> <given-names>C</given-names></name> <name><surname>Iwai</surname> <given-names>K</given-names></name> <name><surname>Mikami</surname> <given-names>R</given-names></name> <name><surname>Hosoda</surname> <given-names>Y</given-names></name></person-group>. <article-title>Frequent isolation of <italic>Propionibacterium acnes</italic> from sarcoidosis lymph nodes</article-title>. <source>Zentralbl Bakteriol Mikrobiol Hyg A</source>. (<year>1984</year>) <volume>256</volume>:<fpage>541</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0174-3031(84)80032-3</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishige</surname> <given-names>I</given-names></name> <name><surname>Usui</surname> <given-names>Y</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Eishi</surname> <given-names>Y</given-names></name></person-group>. <article-title>Quantitative PCR of mycobacterium and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis</article-title>. <source>Lancet</source>. (<year>1999</year>) <volume>354</volume>:<fpage>120</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(98)12310-3</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eishi</surname> <given-names>Y</given-names></name> <name><surname>Suga</surname> <given-names>M</given-names></name> <name><surname>Ishige</surname> <given-names>I</given-names></name> <name><surname>Kobayashi</surname> <given-names>D</given-names></name> <name><surname>Yamada</surname> <given-names>T</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis</article-title>. <source>J Microbiol</source>. (<year>2002</year>) <volume>40</volume>:<fpage>198</fpage>&#x2013;<lpage>204</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.40.1.198-204.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">11773116</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname> <given-names>T</given-names></name> <name><surname>Eishi</surname> <given-names>Y</given-names></name> <name><surname>Ikeda</surname> <given-names>S</given-names></name> <name><surname>Ishige</surname> <given-names>I</given-names></name> <name><surname>Suzuki</surname> <given-names>T</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>In situ localization of <italic>Propionibacterium acnes</italic> DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition</article-title>. <source>J Pathol</source>. (<year>2002</year>) <volume>198</volume>:<fpage>541</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1002/path.1243</pub-id>, PMID: <pub-id pub-id-type="pmid">12434425</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negi</surname> <given-names>M</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Guzman</surname> <given-names>J</given-names></name> <name><surname>Uchida</surname> <given-names>K</given-names></name> <name><surname>Furukawa</surname> <given-names>A</given-names></name> <name><surname>Suzuki</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Localization of <italic>Propionibacterium acnes</italic> in granulomas support a possible etiologic link between sarcoidosis and bacterium</article-title>. <source>Mod Pathol</source>. (<year>2012</year>) <volume>25</volume>:<fpage>1284</fpage>&#x2013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1038/modpathol.2012.80</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eishi</surname> <given-names>Y</given-names></name></person-group>. <article-title>Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by <italic>Propionibacyerium acnes</italic></article-title>. <source>Respir Investig</source>. (<year>2013</year>) <volume>51</volume>:<fpage>56</fpage>&#x2013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/935289</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>Z</given-names></name> <name><surname>Marzilli</surname> <given-names>L</given-names></name> <name><surname>Greenlee</surname> <given-names>BM</given-names></name> <name><surname>Chen</surname> <given-names>ES</given-names></name> <name><surname>Silver</surname> <given-names>RF</given-names></name> <name><surname>Askin</surname> <given-names>FB</given-names></name> <etal/></person-group>. <article-title>Mycobacterial catalases peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis</article-title>. <source>J Exp Med</source>. (<year>2005</year>) <volume>201</volume>:<fpage>755</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20040429</pub-id>, PMID: <pub-id pub-id-type="pmid">15753209</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubaniewicz</surname> <given-names>A</given-names></name> <name><surname>Dubaniewicz-Wybieralska</surname> <given-names>M</given-names></name> <name><surname>Sternau</surname> <given-names>A</given-names></name> <name><surname>Zwolska</surname> <given-names>Z</given-names></name> <name><surname>Izycka-Swieszewska</surname> <given-names>E</given-names></name> <name><surname>Augustynowicz-Kopec</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title><italic>Mycobacterium tuberculosis</italic> complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis</article-title>. <source>J Clin Microbiol</source>. (<year>2006</year>) <volume>44</volume>:<fpage>3448</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.01433-06</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname> <given-names>DR</given-names></name></person-group>. <article-title>Potential etiologic agents in sarcoidosis</article-title>. <source>Proc Am Thorac Soc</source>. (<year>2007</year>) <volume>4</volume>:<fpage>465</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1513/pats.200608-155MS</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname> <given-names>J</given-names></name> <name><surname>Grutters</surname> <given-names>JC</given-names></name> <name><surname>Arkema</surname> <given-names>E</given-names></name> <name><surname>Arkema</surname> <given-names>EV</given-names></name> <name><surname>Saketkoo</surname> <given-names>LA</given-names></name> <name><surname>Moller</surname> <given-names>DR</given-names></name> <etal/></person-group>. <article-title>Sarcoidosis</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2019</year>) <volume>5</volume>:<fpage>45</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41572-019-0096-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31273209</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname> <given-names>M</given-names></name> <name><surname>Uchida</surname> <given-names>k</given-names></name> <name><surname>Furukawa</surname> <given-names>A</given-names></name> <name><surname>Eishi</surname> <given-names>Y</given-names></name> <name><surname>Maemondo</surname> <given-names>M</given-names></name></person-group>. <article-title>Latent microbial reactivation and immune dysregulation in sarcoidosis; bridging pathogenesis and precision therapeutics</article-title>. <source>Front Med</source>. (<year>2025</year>) <volume>12</volume>:<fpage>1625915</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2025.1625915</pub-id>, PMID: <pub-id pub-id-type="pmid">40837573</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname> <given-names>T</given-names></name> <name><surname>Azuma</surname> <given-names>A</given-names></name> <name><surname>Abe</surname> <given-names>S</given-names></name> <name><surname>Usuki</surname> <given-names>J</given-names></name> <name><surname>Kudoh</surname> <given-names>S</given-names></name> <name><surname>Sugisaki</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Epidemiology of sarcoidosis in Japan</article-title>. <source>Eur Respir J</source>. (<year>2008</year>) <volume>31</volume>:<fpage>372</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00075307</pub-id>, PMID: <pub-id pub-id-type="pmid">17959635</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname> <given-names>M</given-names></name> <name><surname>Sugiyama</surname> <given-names>Y</given-names></name> <name><surname>Nakamura</surname> <given-names>Y</given-names></name> <name><surname>Nakayama</surname> <given-names>M</given-names></name> <name><surname>Mato</surname> <given-names>N</given-names></name> <name><surname>Yamasawa</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Age-related differences in chest radiographic staging of sarcoidosis in Japan</article-title>. <source>Eur Respir J</source>. (<year>2014</year>) <volume>43</volume>:<fpage>1810</fpage>&#x2013;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00005414</pub-id></mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname> <given-names>M</given-names></name> <name><surname>Sugiyama</surname> <given-names>Y</given-names></name> <name><surname>Nakamura</surname> <given-names>Y</given-names></name> <name><surname>Nakayama</surname> <given-names>M</given-names></name> <name><surname>Mato</surname> <given-names>N</given-names></name> <name><surname>Yamasawa</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan</article-title>. <source>Respir Med</source>. (<year>2015</year>) <volume>109</volume>:<fpage>272</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rmed.2014.12.012</pub-id></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname> <given-names>K</given-names></name> <name><surname>Tachibana</surname> <given-names>T</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name> <name><surname>Kitalchi</surname> <given-names>M</given-names></name> <name><surname>Kawabata</surname> <given-names>Y</given-names></name></person-group>. <article-title>Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan</article-title>. <source>Acta Pathol Jpn</source>. (<year>1993</year>) <volume>43</volume>:<fpage>372</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1827.1993.tb01148.x</pub-id>, PMID: <pub-id pub-id-type="pmid">8372682</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname> <given-names>K</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Kitaichi</surname> <given-names>M</given-names></name> <name><surname>Kawabata</surname> <given-names>Y</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name></person-group>. <article-title>Pathological studies on sarcoidosis autopsy. Part II. Early change, mode pf progression and death pattern</article-title>. <source>Acta Pathol Jpn</source>. (<year>1993</year>) <volume>43</volume>:<fpage>377</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1827.1993.tb01149.x</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname> <given-names>T</given-names></name> <name><surname>Iwai</surname> <given-names>K</given-names></name> <name><surname>Takemura</surname> <given-names>T</given-names></name></person-group>. <article-title>Sarcoidosis in the aged: review and management</article-title>. <source>Curr Opin Pulm Med</source>. (<year>2010</year>) <volume>16</volume>:<fpage>465</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MCP.0b013e32833ae508</pub-id>, PMID: <pub-id pub-id-type="pmid">20473168</pub-id></mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teirstein</surname> <given-names>AS</given-names></name> <name><surname>Judson</surname> <given-names>MA</given-names></name> <name><surname>Baughman</surname> <given-names>RP</given-names></name> <name><surname>Rossman</surname> <given-names>MD</given-names></name> <name><surname>Yeager</surname> <given-names>H</given-names> <suffix>Jr</suffix></name> <name><surname>Moller</surname> <given-names>DR</given-names></name></person-group>. <article-title>The spectrum of biopsy sites for the diagnosis of sarcoidosis</article-title>. <source>Sarcoidosis Vasc Diffuse Lung Dis</source>. (<year>2005</year>) <volume>22</volume>:<fpage>139</fpage>&#x2013;<lpage>46</lpage>.</mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouser</surname> <given-names>ED</given-names></name> <name><surname>Maier</surname> <given-names>LA</given-names></name> <name><surname>Wilson</surname> <given-names>KC</given-names></name> <name><surname>Bonham</surname> <given-names>CA</given-names></name> <name><surname>Morgenthau</surname> <given-names>AS</given-names></name> <name><surname>Patterson</surname> <given-names>KC</given-names></name> <etal/></person-group>. <article-title>Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2020</year>) <volume>201</volume>:<fpage>e26</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1164/rccm.202002-0251ST</pub-id>, PMID: <pub-id pub-id-type="pmid">32293205</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname> <given-names>T</given-names></name> <name><surname>Yasufuku</surname> <given-names>K</given-names></name> <name><surname>Kurosu</surname> <given-names>K</given-names></name> <name><surname>Takiguchi</surname> <given-names>Y</given-names></name> <name><surname>Fujiwara</surname> <given-names>T</given-names></name> <name><surname>Chiyo</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>The role of EBUS-TBNA for the diagnosis of sarcoidosis-comparison with other bronchoscopic diagnostic modalities</article-title>. <source>Respir Med</source>. (<year>2009</year>) <volume>103</volume>:<fpage>1796</fpage>&#x2013;<lpage>800</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rmed.2009.07.013</pub-id></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetzel</surname> <given-names>J</given-names></name> <name><surname>Maldonado</surname> <given-names>F</given-names></name> <name><surname>Ravaglia</surname> <given-names>C</given-names></name> <name><surname>Wells</surname> <given-names>AU</given-names></name> <name><surname>Colby</surname> <given-names>TV</given-names></name> <name><surname>Tomassetti</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsies working group on safety and utility and a call for standardization of the procedure</article-title>. <source>Respiration</source>. (<year>2018</year>) <volume>95</volume>:<fpage>188</fpage>&#x2013;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000484055</pub-id></mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name> <name><surname>Costabel</surname> <given-names>U</given-names></name> <name><surname>Huang</surname> <given-names>D</given-names></name></person-group>. <article-title>The role of diverse immune cells in sarcoidosis</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>788502</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.788502</pub-id>, PMID: <pub-id pub-id-type="pmid">34868074</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>D</given-names></name> <name><surname>Tao</surname> <given-names>X</given-names></name> <name><surname>Fan</surname> <given-names>Y</given-names></name> <name><surname>Teng</surname> <given-names>Y</given-names></name></person-group>. <article-title>Sarcoidosis: molecular mechanisms and therapeutic strategies</article-title>. <source>Mol Biomed</source>. (<year>2025</year>) <volume>6</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s43556-025-00244-z</pub-id>, PMID: <pub-id pub-id-type="pmid">39904950</pub-id></mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>Y</given-names></name></person-group>. <article-title>Sarcoidosis</article-title> In: <person-group person-group-type="editor"><name><surname>Dail</surname> <given-names>DH</given-names></name> <name><surname>Hammar</surname> <given-names>SP</given-names></name></person-group>, editors. <source>Pulmonary pathology</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name> (<year>1993</year>). <fpage>615</fpage>.</mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonham</surname> <given-names>CA</given-names></name> <name><surname>Strek</surname> <given-names>ME</given-names></name> <name><surname>Patterson</surname> <given-names>KC</given-names></name></person-group>. <article-title>From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis</article-title>. <source>Curr Opin Pulm Med</source>. (<year>2016</year>) <volume>22</volume>:<fpage>484</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MCP.0000000000000301</pub-id>, PMID: <pub-id pub-id-type="pmid">27379967</pub-id></mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeratunga</surname> <given-names>P</given-names></name> <name><surname>Moller</surname> <given-names>DR</given-names></name> <name><surname>Ho</surname> <given-names>LP</given-names></name></person-group>. <article-title>Immune mechanisms in fibrotic pulmonary sarcoidosis</article-title>. <source>Eur Respir Rev</source>. (<year>2022</year>) <volume>31</volume>:<fpage>220178</fpage>. doi: <pub-id pub-id-type="doi">10.1183/16000617.0178-2022</pub-id>, PMID: <pub-id pub-id-type="pmid">36543347</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname> <given-names>D</given-names></name> <name><surname>Mirsaeidi</surname> <given-names>MS</given-names></name></person-group>. <article-title>Sarcoidosis-associated pulmonary fibrosis: joining the dots</article-title>. <source>Eur Respir Rev</source>. (<year>2023</year>) <volume>32</volume>:<fpage>230085</fpage>. doi: <pub-id pub-id-type="doi">10.1183/16000617.0085-2023</pub-id>, PMID: <pub-id pub-id-type="pmid">37758275</pub-id></mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname> <given-names>H</given-names></name> <name><surname>Brillet</surname> <given-names>P-Y</given-names></name> <name><surname>Bernaudin</surname> <given-names>J-F</given-names></name> <name><surname>Gille</surname> <given-names>T</given-names></name> <name><surname>Valeyre</surname> <given-names>D</given-names></name> <name><surname>Jeny</surname> <given-names>F</given-names></name></person-group>. <article-title>Fibrotic pulmonary sarcoidosis</article-title>. <source>Clin Chest Med</source>. (<year>2024</year>) <volume>45</volume>:<fpage>199</fpage>&#x2013;<lpage>212</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ccm.2023.08.011</pub-id>, PMID: <pub-id pub-id-type="pmid">38245367</pub-id></mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name> <name><surname>Oritsu</surname> <given-names>M</given-names></name> <name><surname>Akiyama</surname> <given-names>O</given-names></name> <name><surname>Hiraga</surname> <given-names>Y</given-names></name> <name><surname>Omichi</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies</article-title>. <source>Virchows Arch A Pathol Anat Histopathol</source>. (<year>1991</year>) <volume>418</volume>:<fpage>361</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF01600167</pub-id>, PMID: <pub-id pub-id-type="pmid">1850897</pub-id></mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname> <given-names>M</given-names></name> <name><surname>Kozuka</surname> <given-names>T</given-names></name> <name><surname>Inoue</surname> <given-names>Y</given-names></name> <name><surname>Sakatani</surname> <given-names>M</given-names></name></person-group>. <article-title>Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis</article-title>. <source>Chest</source>. (<year>2005</year>) <volume>127</volume>:<fpage>185</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1378/chest.127.1.185</pub-id>, PMID: <pub-id pub-id-type="pmid">15653982</pub-id></mixed-citation></ref>
<ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Ikushima</surname> <given-names>S</given-names></name> <name><surname>Ando</surname> <given-names>T</given-names></name> <name><surname>Yanagawa</surname> <given-names>T</given-names></name> <name><surname>Akiyama</surname> <given-names>O</given-names></name> <name><surname>Oritsu</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Remodeling of the lung in sarcoidosis: a pathological study of 66 autopsy cases</article-title>. <source>Jpn J Sarcoidosis Other Granulomatous Disord</source>. (<year>2003</year>) <volume>23</volume>:<fpage>43</fpage>&#x2013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.14830/jssog1999.23.43</pub-id></mixed-citation></ref>
<ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname> <given-names>M</given-names></name> <name><surname>Johkoh</surname> <given-names>T</given-names></name> <name><surname>Kawanobe</surname> <given-names>T</given-names></name> <name><surname>Kono</surname> <given-names>C</given-names></name> <name><surname>Nakamura</surname> <given-names>Y</given-names></name> <name><surname>Bando</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Computed tomography images of fibtrooic pulmonary sarcoidosis leading to chronic respiratory failure</article-title>. <source>J Clin Med</source>. (<year>2020</year>) <volume>9</volume>:<fpage>142</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm9010142</pub-id></mixed-citation></ref>
<ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawanobe</surname> <given-names>T</given-names></name> <name><surname>Yamaguchi</surname> <given-names>T</given-names></name> <name><surname>Johkoh</surname> <given-names>T</given-names></name> <name><surname>Kono</surname> <given-names>C</given-names></name> <name><surname>Sawahata</surname> <given-names>M</given-names></name> <name><surname>Shijubo</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Central bronchial deformity in pulmonary sarcoidosis: a finding suggestive of an upper lobe fibrotic phenotype on chest images</article-title>. <source>Acad Radiol</source>. (<year>2024</year>) <volume>31</volume>:<fpage>1160</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.acra.2023.08.034</pub-id>, PMID: <pub-id pub-id-type="pmid">37743162</pub-id></mixed-citation></ref>
<ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Eishi</surname> <given-names>Y</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name></person-group>. <article-title>An autopsy case of sarcoidosis followed up for 27 years with special reference to pulmonary fibrosis</article-title>. <source>Acta Pathol Jpn</source>. (<year>1988</year>) <volume>38</volume>:<fpage>909</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1827.1988.tb02362.x</pub-id>, PMID: <pub-id pub-id-type="pmid">2847479</pub-id></mixed-citation></ref>
<ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigemitsu</surname> <given-names>H</given-names></name> <name><surname>Oblad</surname> <given-names>JM</given-names></name> <name><surname>Sharma</surname> <given-names>OP</given-names></name> <name><surname>Koss</surname> <given-names>MN</given-names></name></person-group>. <article-title>Chronic interstitial pneumonitis in end-stage sarcoidosis</article-title>. <source>Eur Respir J</source>. (<year>2010</year>) <volume>35</volume>:<fpage>695</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00150609</pub-id>, PMID: <pub-id pub-id-type="pmid">20190336</pub-id></mixed-citation></ref>
<ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigemitsu</surname> <given-names>H</given-names></name> <name><surname>Azuma</surname> <given-names>A</given-names></name></person-group>. <article-title>Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum</article-title>. <source>Curr Opin Pulm Med</source>. (<year>2011</year>) <volume>17</volume>:<fpage>303</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MCP.0b013e3283486d52</pub-id>, PMID: <pub-id pub-id-type="pmid">21681100</pub-id></mixed-citation></ref>
<ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname> <given-names>K</given-names></name> <name><surname>Arai</surname> <given-names>T</given-names></name> <name><surname>Kagawa</surname> <given-names>T</given-names></name> <name><surname>Minomo</surname> <given-names>S</given-names></name> <name><surname>Akira</surname> <given-names>M</given-names></name> <name><surname>Kitaichi</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>A case of combined sarcoidosis and usual interstitial pneumonia</article-title>. <source>Intern Med</source>. (<year>2012</year>) <volume>51</volume>:<fpage>1893</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.2169/internalmedicine.51.7394</pub-id>, PMID: <pub-id pub-id-type="pmid">22821108</pub-id></mixed-citation></ref>
<ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>BF</given-names></name> <name><surname>McClelland</surname> <given-names>RL</given-names></name> <name><surname>Ho</surname> <given-names>LA</given-names></name> <name><surname>Mikacenic</surname> <given-names>CR</given-names></name> <name><surname>Hayes</surname> <given-names>J</given-names></name> <name><surname>Spada</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?</article-title> <source>Respir Med</source>. (<year>2018</year>) <volume>144</volume>:<fpage>S20</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rmed.2018.08.008</pub-id>, PMID: <pub-id pub-id-type="pmid">30166087</pub-id></mixed-citation></ref>
<ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname> <given-names>K</given-names></name> <name><surname>Akira</surname> <given-names>M</given-names></name> <name><surname>Arai</surname> <given-names>T</given-names></name> <name><surname>Sugimoto</surname> <given-names>C</given-names></name> <name><surname>Hayashi</surname> <given-names>S</given-names></name> <name><surname>Inoue</surname> <given-names>Y</given-names></name></person-group>. <article-title>Poor outcome and mortality in patients with lower lung-dominant sarcoidosis</article-title>. <source>Can Respir J</source>. (<year>2023</year>) <volume>2023</volume>:<fpage>3624344</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2023/3624344</pub-id>, PMID: <pub-id pub-id-type="pmid">37096167</pub-id></mixed-citation></ref>
<ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>Y</given-names></name> <name><surname>Moon</surname> <given-names>S</given-names></name> <name><surname>Huang</surname> <given-names>CT</given-names></name> <name><surname>Gourin</surname> <given-names>A</given-names></name> <name><surname>Lyons</surname> <given-names>HA</given-names></name></person-group>. <article-title>Granulomatous pulmonary angiitis in sarcoidosis</article-title>. <source>Arch Pathol Lab Med</source>. (<year>1977</year>) <volume>101</volume>:<fpage>170</fpage>&#x2013;<lpage>4</lpage>.</mixed-citation></ref>
<ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Saiki</surname> <given-names>S</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name> <name><surname>Mikami</surname> <given-names>R</given-names></name></person-group>. <article-title>Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases</article-title>. <source>Hum Pathol</source>. (<year>1992</year>) <volume>23</volume>:<fpage>1216</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0046-8177(92)90288-e</pub-id>, PMID: <pub-id pub-id-type="pmid">1427751</pub-id></mixed-citation></ref>
<ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savale</surname> <given-names>L</given-names></name> <name><surname>Huitema</surname> <given-names>M</given-names></name> <name><surname>Shlobin</surname> <given-names>O</given-names></name> <name><surname>Kouranos</surname> <given-names>V</given-names></name> <name><surname>Nathan</surname> <given-names>SD</given-names></name> <name><surname>Nunes</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension</article-title>. <source>Eur Respir Rev</source>. (<year>2022</year>) <volume>31</volume>:<fpage>210165</fpage>. doi: <pub-id pub-id-type="doi">10.1183/16000617.0165-2021</pub-id></mixed-citation></ref>
<ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikami</surname> <given-names>R</given-names></name> <name><surname>Sekiguchi</surname> <given-names>M</given-names></name> <name><surname>Ryuzin</surname> <given-names>Y</given-names></name> <name><surname>Kobayashi</surname> <given-names>F</given-names></name> <name><surname>Hiraga</surname> <given-names>Y</given-names></name> <name><surname>Shimada</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Changes in peripheral vasculature of various organs in patients with sarcoidosis. &#x2013;possible role of microangiopathy</article-title>. <source>Heart Vessel</source>. (<year>1986</year>) <volume>2</volume>:<fpage>129</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02128138</pub-id></mixed-citation></ref>
<ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>T</given-names></name> <name><surname>Hiraga</surname> <given-names>Y</given-names></name> <name><surname>Oomichi</surname> <given-names>M</given-names></name> <name><surname>Oritsu</surname> <given-names>M</given-names></name> <name><surname>Akiyama</surname> <given-names>O</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Ultrastructural features of alveolitis in sarcoidosis</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>1995</year>) <volume>152</volume>:<fpage>360</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1164/ajrccm.152.1.7599846</pub-id>, PMID: <pub-id pub-id-type="pmid">7599846</pub-id></mixed-citation></ref>
<ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>KC</given-names></name> <name><surname>Kaminski</surname> <given-names>MJ</given-names></name> <name><surname>Calhoun</surname> <given-names>WJ</given-names></name> <name><surname>Auerbach</surname> <given-names>R</given-names></name></person-group>. <article-title>Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis <italic>in vivo</italic></article-title>. <source>Am Rev Respir Dis</source>. (<year>1989</year>) <volume>140</volume>:<fpage>1446</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1164/ajrccm/140.5.1446</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1506407/overview">Yoshinobu Eishi</ext-link>, Tokyo Medical and Dental University, Japan</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2009854/overview">Yasuo Shimizu</ext-link>, Dokkyo Medical University School of Medicine, Japan</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3232817/overview">Likhita Shaik</ext-link>, University of Iowa Sleep Disorders Center, United States</p>
</fn>
</fn-group>
</back>
</article>